Objectif The objective of the innovation project is to develop and clinically validate the first diagnostic device for the early detection of diabetic neuropathy (also referred to as diabetic foot). Diabetic foot is a common complication of both type 1 and type 2 diabetes. Current methods are only able to detect diabetic foot once the patient is already experiencing loss of sensation. This can result in an increased number of amputations and costs as a result of those amputations. The disruptiveness and the market potential of the new device lie in its capacity to identify diabetic neuropathy at a very early stage. The device will fill the identified niche on the market and contribute to better clinical outcomes for the patients. The main need of the users (physicians, nurses, policy makes, and patients) is access to an efficient dependable method for early detection of diabetic neuropathy. These needs will be met through the prototype device allowing physicians and nurses to assess the condition and determine appropriate treatment. The Phase 1 project will develop a strategic business plan for the commercialisation of the innovative diagnostic device for the early detection of diabetic neuropathy. The project will strengthen VibroSense’s understanding of the European market in general and verify the economic viability of the clinical validation to be pursued within the Phase 2 project. The late diagnosis of diabetic foot results in patient’s suffering and substantial health-care costs. It is estimated that approximately 1/9 of the total healthcare expenditures in Europe is spent on diabetes, with foot care being one of the more dominant costs. The project addresses this EU-wide challenge by proposing a new early-diagnostic method. The new device will build a strong case for introducing more cost-effective, personalised medicine approaches in the management of diabetic foot. The commercial output will be new competitive advantages and accelerated growth for VibroSense. Champ scientifique medical and health scienceshealth sciencespublic healthepidemiologypandemicsmedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesbasic medicineimmunologyautoimmune diseasesmedical and health scienceshealth sciencesnutritionmedical and health scienceshealth sciencespersonalized medicine Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Appel à propositions H2020-SMEInst-2014-2015 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2015 Régime de financement SME-1 - SME instrument phase 1 Coordinateur VIBROSENSE DYNAMICS AB Contribution nette de l'UE € 50 000,00 Adresse MEDEON SCIENCE PARK PER ALBIN HANS 20512 MALMO Suède Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Södra Sverige Sydsverige Skåne län Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
